Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Leyden Labs acquires RIGImmune for new therapies

PRIVATESep 09, 2026about 3 hours ago

Acquiring Company

Leyden Labs

Acquired Company

RIGImmune

FarmingtonScience And EngineeringBiotechnologyTherapeutics

Description

Leyden Labs has officially acquired RIGImmune, expanding its pipeline into mucosal protection therapies. The acquisition was confirmed in an email to European Biotechnology, with Leyden noting that it complements their existing approach. RIGImmune's technology is expected to play a key role in Leyden's development strategy. Financial details were not disclosed, but prior filings indicate share exchanges as part of the acquisition.

Company Information

Company

Leyden Labs

About

The platform will also support development of novel broad-protection nasal sprays for coronavirus family and other respiratory diseases. “This fundraising underscores our investors’ belief that Leyden Labs’ platform can generate cornerstone products to combat respiratory diseases. Leyden Labs has a pipeline of mucosal protection products, including PanFlu which uses CR9114, the only human monoclonal influenza antibody that protects against influenza A and B, in-licensed from Janssen Pharmaceuticals.

Don't miss Leyden Labs's next move

Get an email the moment Leyden Labs makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Joost
Likely contact at this company
••••••••@••••••••

See Joost's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Leyden Labs's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired RIGImmune?

RIGImmune was acquired by Leyden Labs. The deal was reported on September 9, 2026. The platform will also support development of novel broad-protection nasal sprays for coronavirus family and other respiratory diseases. Leyden Labs is privately held and operates in Science And Engineering.

When did Leyden Labs acquire RIGImmune?

Leyden Labs's acquisition of RIGImmune was reported on September 9, 2026. Leyden Labs has officially acquired RIGImmune, expanding its pipeline into mucosal protection therapies. The acquisition was confirmed in an email to European Biotechnology, with Leyden noting that it complements their existing approach. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does RIGImmune do?

RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies termed “SLRs” for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. It is privately held, operating in Biotechnology, and is based in Farmington.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.